Lorusso D - Search Results

1

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA. Mirza MR, et al. Among authors: lorusso d. Gynecol Oncol. 2020 Nov;159(2):442-448. doi: 10.1016/j.ygyno.2020.09.006. Epub 2020 Sep 25. Gynecol Oncol. 2020. PMID: 32981695 Clinical Trial.

2

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.

Greggi S, Salerno MG, D'Agostino G, Ferrandina G, Lorusso D, Manzione L, Mancuso S, Scambia G. Greggi S, et al. Among authors: d agostino g, lorusso d. Oncology. 2001;60(1):19-23. doi: 10.1159/000055291. Oncology. 2001. PMID: 11150903 Clinical Trial.

3

Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.

D'Agostino G, Ferrandina G, Garganese G, Salerno MG, Lorusso D, Farnetano MG, Mancuso S, Scambia G. D'Agostino G, et al. Among authors: lorusso d. Oncology. 2002;62(2):110-4. doi: 10.1159/000048255. Oncology. 2002. PMID: 11914595 Clinical Trial.

4

Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?

Lorusso D, Naldini A, Testa A, D'Agostino G, Scambia G, Ferrandina G. Lorusso D, et al. Among authors: d agostino g. Oncology. 2004;67(3-4):243-9. doi: 10.1159/000081324. Oncology. 2004. PMID: 15557785 Clinical Trial.

5

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.

Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Ferrandina G, et al. Among authors: d agostino g, lorusso d. Gynecol Oncol. 2005 Aug;98(2):267-73. doi: 10.1016/j.ygyno.2005.04.018. Gynecol Oncol. 2005. PMID: 15975643 Clinical Trial.

6

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

Ferrandina G, Ludovisi M, De Vincenzo R, Salutari V, Lorusso D, Colangelo M, Prantera T, Valerio MR, Scambia G. Ferrandina G, et al. Among authors: lorusso d. Ann Oncol. 2007 Aug;18(8):1348-53. doi: 10.1093/annonc/mdm136. Epub 2007 Apr 29. Ann Oncol. 2007. PMID: 17470449 Free article. Clinical Trial.

7

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.

Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F. Pignata S, et al. Among authors: lorusso d. Crit Rev Oncol Hematol. 2008 Jun;66(3):229-36. doi: 10.1016/j.critrevonc.2007.12.005. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243011 Clinical Trial.

8

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.

Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Pignata S, et al. Among authors: lorusso d. Oncology. 2009;76(1):49-54. doi: 10.1159/000178760. Epub 2008 Nov 27. Oncology. 2009. PMID: 19039248 Clinical Trial.

9

Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).

Mangili G, Scarfone G, Gadducci A, Sigismondi C, Ferrandina G, Scibilia G, Viganò R, Tateo S, Villa A, Lorusso D. Mangili G, et al. Among authors: lorusso d. Gynecol Oncol. 2010 Oct;119(1):48-52. doi: 10.1016/j.ygyno.2010.05.035. Gynecol Oncol. 2010. PMID: 20599258

10

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Harter P, et al. Among authors: lorusso d. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd. Int J Gynecol Cancer. 2011. PMID: 21270612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

502 results

Search Page